Companies › Beijing Zhifei Lvzhu Biopharmaceutical
3 active drug programs in 3 registered trials: 3 Phase 3; Other, Infectious disease; next expected readout Jun 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| 23 Valent Pneumococcal Polysaccharide Vaccine (PPSV23) Polysaccharide vaccine containing capsular polysaccharides from 23 Streptococcus pneumonia | – | Phase 3 | Healthy Volunteers | Jun 2028 |
| S. Flexneri-S. Sonnei bivalent conjugate vaccine Conjugate vaccine against Shigella flexneri and Shigella sonnei | – | Phase 3 | Dysentery | Jul 2028 |
| Diphtheria, tetanus and acellular pertussis (component) combined vaccine (adsorb DTaP vaccine - inactivated toxoids and acellular pertussis antigens | – | Phase 3 | Healthy Volunteers | Dec 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06314867 | 23 Valent Pneumococcal Polysaccharide Vaccine (PPSV23) | Phase 3 | Healthy Volunteers | Other | Jun 2028 |
| NCT06838195 | S. Flexneri-S. Sonnei bivalent conjugate vaccine | Phase 3 | Dysentery | Infectious disease | Jul 2028 |
| NCT06344065 | Diphtheria, tetanus and acellular pertussis (component) combined vaccine (adsorb | Phase 3 | Healthy Volunteers | Other | Dec 2028 |
No annotated target.
–
Aesculap Biologics Metcela OHB Pediatrics CoNextions Medical ULURU
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.